BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bausch & Lomb Introduces INCISE® Microincision Intraocular Lens in Europe


5/2/2013 10:11:43 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ALISO VIEJO, Calif. and KINGSTON, England, May 2, 2013 /PRNewswire/ -- Bausch + Lomb, the global eye health company, announces the launch of its new INCISE®microincision intraocular lens (IOL). This enhanced acrylic IOL, in combination with the capabilities of the Stellaris® Vision Enhancement System, allows surgeons to perform microincision cataract surgery less than 2mm, delivering less invasive surgery for a more rapid visual recovery.[1]

(Photo: http://photos.prnewswire.com/prnh/20130502/NY04776 )

The new lens offers a number of features to deliver an enhanced experience for both the surgeon and patient and ultimately better outcomes. The INCISE IOL's aspheric advanced optics are designed to enhance visual quality.[2] The combination of an enhanced acrylic, improved Stellaris system capabilities and a new single use INCISE Viscoject Bioinjector enables 1.8mm in-the-bag and 1.4mm wound assist implantation enabling surgeons to benefit from a controlled sub-2mm MICS procedure.

INCISE has been designed to minimise posterior capsular opacification (PCO), a common long-term problem with IOLs that can cause patient vision to become clouded post-surgery. INCISE has a 360 degree barrier edge with a radius of curvature of 5 micro-m.[3] "INCISE has a much better edge profile than previous hydrophilic IOLs and has the best edge of any IOL we have ever imaged," said professor David Spalton, St. Thomas' Hospital, London, U.K.

"Sub-2mm cataract surgery with implantation of the INCISE IOL is a safe and effective micro-incision procedure," said university professor, Burkhard Dick, University of Bochum, Germany. "The unfolding of the lens was well controlled, allowing easy placement in the capsular bag. Overall, the performance of this new IOL during implantation and placement in the capsule was easy and predictable."

"The new INCISE lens is the latest innovation from Bausch + Lomb designed to meet the needs of both customers and patients. The combination of the enhanced material in the IOL and the new Viscoject Bio injector enables surgeons to deliver predictable injection performance and optical quality for sub-2mm delivery," said Cal Roberts, M.D., executive vice president and chief medical officer, Bausch + Lomb. "The addition of this next generation lens to our portfolio adds an exciting new option for ophthalmic surgeons performing micro-incision surgery."

The INCISE lens received CE Mark approval in the European Union and is not approved for sale in the U.S.

About Bausch + Lomb
Bausch + Lomb is a leading global eye health company that is solely focused on protecting, enhancing, and restoring people's eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses and lens care products, and ophthalmic surgical devices and instruments. We globally develop, manufacture and market one of the most comprehensive product portfolios in our industry, which are available in more than 100 countries. Founded in 1853, our company is headquartered in Rochester, NY, and employs more than 11,000 people worldwide.

REFERENCES

[1] Kelman CD. Preface. In: Alio JL, Rodriguez Prats JL, Galal A, eds. "MICS Micro-incision Cataract Surgery," Miami: Highlights of Ophthalmology; 2004 /// 2. Agarwal A, et al. "Bimanual phaco. Mastering the phakonit/MICs technique," New Jersey: Slack Inc; 2004) // 3. Zheng L, Merriam JC, Zaider M. Astigmatism and visual recovery after large incision extracapsular cataract surgery and small incisions for phacoemulsification.
Trans Am Ophthalmol 1997; 95: 387-410».

[2] Altmann GE, Nichamin LD, Lane SS, Pepose JS. Optical performance of 3 intraocular lens designs in the presence of decentration. J Cataract Refract Surg. 2005; 31: 574-85.

[3] Spalton; Werner; Nishi: Edge profile is the most important preventing PCO /// Findl ;Cochrane analysis: PCO score lower with sharp edge design, no evidence of contributing role of the optic material.

®/ are trademarks of Bausch & Lomb Incorporated or its affiliates.
© Bausch & Lomb Incorporated.

SOURCE Bausch + Lomb



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES